{"slideshow_credits": null, "snippet": "Documents released by a congressional panel show that Valeant Pharmaceuticals and Turing Pharmaceuticals, Mr. Shkreli\u2019s former company, sometimes raised prices as much as fiftyfold.", "abstract": "Documents released by congressional investigators looking into increases in drug prices reveal Martin Shkreli of Turing Pharmaceuticals was focused solely on profit when company increased price of drug Daraprim by over fifty times; documents also show Valeant Pharmaceuticals International had carefully researched how much it could raise prices of heart drugs Isuprel and Nitropress before acquiring them and steeply increasing prices overnight.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}, {"firstname": "Matthew", "role": "reported", "lastname": "GOLDSTEIN", "rank": 2, "organization": ""}], "original": "By ANDREW POLLACK and MATTHEW GOLDSTEIN"}, "web_url": "http://www.nytimes.com/2016/02/03/business/drug-makers-calculated-price-increases-with-profit-in-mind-memos-show.html", "lead_paragraph": "Documents released by a congressional panel show that Valeant Pharmaceuticals and Turing Pharmaceuticals, Mr. Shkreli\u2019s former company, sometimes raised prices as much as fiftyfold.", "headline": {"main": "Martin Shkreli All but Gloated Over Huge Drug Price Increases, Memos Show", "print_headline": "Email Shows Profit Drove Drug Pricing "}, "_id": "56b1091138f0d873ef2950ed", "word_count": "1284", "multimedia": [{"height": 126, "url": "images/2016/02/03/business/03DRUGalt/03DRUGalt-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/02/03/business/03DRUGalt/03DRUGalt-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2016/02/03/business/03DRUGalt/03DRUGalt-articleLarge.jpg", "legacy": {"xlarge": "images/2016/02/03/business/03DRUGalt/03DRUGalt-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/02/03/business/03DRUGalt/03DRUGalt-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/02/03/business/03DRUGalt/03DRUGalt-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-02-03T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "persons", "value": "Shkreli, Martin (1983- )", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Turing Pharmaceuticals AG", "is_major": "Y", "rank": "3"}, {"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "4"}, {"name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "House Committee on Oversight and Government Reform", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}